Oncology Data Advisor

Click here to view the full activity and claim free NCPD credit! https://i3health.com/course-information/managing-immune-related-adverse-events-to-ensure-optimal-cancer-immunotherapy-outcomes-the-nurses-view At last year’s Greater Los Angeles Oncology Nursing Society (GLAONS) Oncology Care Summit, i3 Health hosted a nursing continuing professional development (NCPD) symposium entitled Managing Immune-Related Adverse Events to Ensure Optimal Cancer Immunotherapy Outcomes (IRAEs): The Nurse’s View, chaired by Blanca Ledezma, MSN, NP, AOCNP®, Hematology/Oncology Nurse Practitioner at UCLA Health. With numerous advances in the immunotherapy space occurring since the symposium was held, Oncology Data Advisor Editorial Board member Beth Sandy, MSN, CRNP, Outpatient Thoracic Oncology Nurse Practitioner at the University of Pennsylvania Abramson Cancer Center, sat down to discuss some of these updates in lung cancer and her own insights on optimal management of IRAEs from the nursing perspective.

In this episode of Exploring Artificial Intelligence (AI) in Oncology, Dr. Waqas Haque sits down with Dana Brown, the President, CEO, and Chairman of the Board at iCAD, a company whose mission is to use innovative AI solutions that empower providers to accurately, reliably, and quickly detect cancer and improve outcomes. Ms. Brown shares more about iCAD’s products and recommendations for how to integrate AI into the clinic, including: • Her own background in the technology industry and why she joined iCAD • The products and solutions that iCAD offers • How iCAD utilizes AI to improve mammography accuracy • The ProFound Breast Health Suite and how it enhances cancer detection and patient outcomes • Their recent partnership with Densitas and CancerIQ and their impact on breast health • What distinguishes iCAD’s AI algorithms from other solutions in the market • The importance of company culture in driving success of AI startups and defining traits behind iCAD’s success • Recommendations for clinicians in prac

In this Fellows Forum podcast episode, Dr. Richa Thakur, Palliative Care Physician and Hematology/Oncology Fellow at Northwell Health, speaks with Dr. Janet Abrahm, one of the founders of the field of palliative care in the United States. Dr. Abrahm shares insights into her career and research in palliative care, including: • How palliative care in oncology isn’t just for end of life—it’s for enhancing patient outcomes • How palliative care serves as a partner for the oncology team • The value of palliative care training for hematology/oncology fellows • How to cope with the moral distress and compassion fatigue that clinicians may experience when treatment doesn’t work for their patients • The stages of grief (denial, anger, bargaining, depression, acceptance) and how they can be experienced by both patients and clinicians • The importance for both oncology and palliative care fellows to find an outlet for their grief • Dr. Abrahm’s website and book, “Comprehensive Guide to Supportive and Palliative Car

In this episode of Exploring Artificial Intelligence in Oncology, Dr. Waqas Haque sits down with Luis Valente, CEO and Co-Founder of iLoF, a digital health company pioneering a breakthrough AI platform to accelerate the future of personalized drug discovery and development.

In this episode of Exploring Artificial Intelligence in Oncology, Dr. Waqas Haque sits down with Dr. Tamir Wolf, Co-Founder and CEO of Theator, a company pioneering next-generation AI and computer vision technology to automatically capture and analyze surgical data in real time to generate actionable insights and improve surgical outcomes.

Combating Health Disparities Through More Equitable Screening: Chyke Doubeni, MD, MPH by i3 Health

Multicancer Early Detection - What's Your Opinion? with Chyke Doubeni, MD, MPH by i3 Health

The Latest Data on Zanidatamab for HER2-Positive Biliary Tract Cancer: Shubham Pant, MD by i3 Health

Biomarker Documentation in the Community Setting and Clinical Decision Support: Daniel Rubin, PharmD by i3 Health

Community Oncology Pharmacists - Their Crucial Role and Clinical Impact: Andrea Roman, PharmD, BCOP by i3 Health

Cancer + Careers - Empowering People with Cancer to Thrive in the Workplace: Rebecca Nellis, MPP by i3 Health

Exploring Association of FGFR3 Alterations in Urothelial Cancer: Arlene Siefker-Radtke, MD by i3 Health

Representing Symptom Research and Nursing at ASCO: Natalie Jackson-Carroll, PhD, APRN, FNP-C by i3 Health

Worth the Wait - Supporting Young Adult Cancer Survivors on the Path to Parenthood: Mike Scherer by i3 Health

Optimizing Sacituzumab Govitecan Tolerability in TNBC With Early Management: Antonio Llombart, MD by i3 Health

Investigating Axicabtagene Ciloleucel for R/R Central Nervous System Lymphoma: Lakshmi Nayak, MD by i3 Health

Understanding Lung Cancer Diagnostic Trends to Inform Therapeutic Development: Jess Paulus, SCd by i3 Health

Intuitively Designing Clinical Trials to Empower Patients: Ishwaria Subbiah, MD by i3 Health

Updated Results from the SPOTLIGHT and EV-302 Trials at ASCO: Ahsan Arozullah, MD, MPH by i3 Health

At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Oncology Data Advisor sat down with Erica Fortune, PhD, Vice President of Research at Cancer Support Community, to discuss her team’s poster entitled, “Head and Neck Cancer (HNC) Survivors: Long-Term Nutrition Impact Symptoms, Eating Problems, and Barriers to Care Impact Psychosocial Health.” In this podcast, Dr. Fortune delves further into this topic, including: Background about long-term side effects and quality-of-life impacts experienced by HNC survivors Cancer Support Community’s survey designed to further investigate these challenges The results that the study found regarding nutrition, eating problems, and barriers to care that survivors experience How Cancer Support Community plans on using the survey results to improve survivorship and address psychosocial impacts experienced by long-term HNC survivors A preview of other topics that Cancer Support Community is excited to cover as a member organization of the Oncolog